[Estimation of therapeutical efficacy of weak variable magnetic fields with low value of induction in patients with depression].
OBJECTIVE
Preliminary results of research on the therapeutical efficacy of weak variable magnetic fields with low value of induction used as magnetostimulation in patients with depression not reacting to two consecutive, correctly applied anti-depressant pharmacological treatment are presented in the paper.


METHODS
The examined patients (24 persons aged 18-65 years) treated with anti-depressants accessible in Poland were randomly divided into 2 groups. In 1 group (11 persons--9 women and 2 men) magnetostimulation with the use of a weak variable magnetic field with a low value of induction of 15 microT generated by the VIOFOR JPS device (Poland) lasting 12 minutes daily for 15 days was added to pharmacological therapy. Patients from 2 groups (13 persons--11 women and 2 men) were exposed to exposure with the same device. The intensity of depression was estimated with Beck's, Montgomery-Asberg's and Hamilton's scales.


RESULTS
As a result of a cycle of active magnetostimulation a distinct, statistically significant decrease of intensification of depression, both in the 7th and 15th day exposure was obtained, while in the sham-exposed group only slight, transient decrease of intensification of depression in the 7th day of sham-exposure was observed.


CONCLUSIONS
It was concluded that adding magnetostimulation to pharmacological therapy results in a progressive, significant reduction of intensification of depression symptoms.
Z Katedry i Kliniki Chorób Wewnetrznych i Medycyny Fizykalnej Wydziału Lekarskiego w Zabrzu Slaskiej AM w Katowicach.
Aleksander
A
Sieroń
Robert T
RT
Hese
Jarosław
J
Sobiś
Grzegorz
G
Cieślar
D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy*; D004574:Electromagnetic Fields; D005260:Female; D016666:Fluvoxamine / Q000008:administration & dosage; D006801:Humans; D008280:Magnetics / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000008:administration & dosage; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D017374:Paroxetine; D016666:Fluvoxamine